ArticleAsian Pacific journal of cancer prevention : APJCP2026
Sesamin Mitigates Gastric Carcinogenesis via Modulation of the PI3K/AKT/mTOR Signaling Pathway in AGS Cells and MNNG-Induced Rats.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is a leading cause of cancer-related death worldwide, frequently associated with dysregulated PI3K/AKT/mTOR signaling and defective apoptosis. Sesamin, a lignan from sesame seeds, is rich in antioxidant and anticancer activities, yet it has not been well investigated for its therapeutic potential in GC.
objectiveThis study aims to investigate the anticancer potential of sesamin against gastric cancer by targeting the PI3K/AKT/mTOR signaling pathway in AGS cells and MNNG-induced rats, evaluating its effects on apoptosis, oxidative stress, and tumor biomarkers to elucidate its molecular mechanism of action.
methodsIn vitro, molecular changes in AGS gastric cancer (GC) cells were determined by RT-PCR (p53, caspase-3, MDM2, PTEN, AKT, mTOR, NF-κB). In vivo, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) was used to induce gastric cancer in Wistar rats. The intervention of sesamin was studied by histopathological analysis, and ELISA was used for the measurement of tumor markers (CEA and CA 19-9) and oxidative stress markers. Gene expression was analyzed by RT-PCR (p53, caspase-3, AKT, NF-κB, mTOR).
resultsSesamin treatment in AGS cells upregulated PTEN, p53, and caspase-3, while downregulating MDM2, AKT, mTOR, and NF-κB at the mRNA level in the in vitro study. In the in vivo mRNA expression analysis, sesamin treatment confirmed enhanced p53 and caspase-3 with reduced AKT expression and slightly increased mTOR expression. In MNNG-induced rats, sesamin improved gastric histology, decreased tumor markers (CEA, CA 19-9), suppressed IL-1β, and elevated GSH. RT-PCR analysis further validated the induction of pro-apoptotic genes and suppression of oncogenic PI3K/AKT/mTOR/NF-κB signaling, consistent with in vitro findings.
conclusionSesamin has demonstrated effective anti-gastric cancer activity by inducing p53/caspase-3-mediated apoptosis and inhibiting the PI3K/AKT/mTOR/NF-κB signaling pathway. These findings illustrate the therapeutic potential of sesamin against gastric cancer and reveal molecular clues for its use as a natural chemopreventive agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.